How to buy Regeneron Pharmaceuticals (REGN) shares in the UK

Learn how to easily invest in Regeneron Pharmaceuticals shares.

Regeneron Pharmaceuticals Inc (REGN) is a publicly traded biotechnology business based in the US. In the week up to 8 August Regeneron Pharmaceuticals shares surged 9.36% to a closing position of $630.63. Over the last 12 months, Regeneron Pharmaceuticals's share price has risen by 2.54% from $608.45. Regeneron Pharmaceuticals is listed on the NASDAQ and employs 10,368 staff. All prices are listed in US Dollars.

How to buy shares in Regeneron Pharmaceuticals

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: REGN in this case.
  5. Research Regeneron Pharmaceuticals shares. The platform should provide the latest information available.
  6. Buy your Regeneron Pharmaceuticals shares. It's that simple.
The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Fees for buying 5x Regeneron Pharmaceuticals shares with popular platforms

Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.

Platform Platform fee Min. initial deposit Trading fee estimate
eToro Free Stocks logo £0 $10 £12.79
£2,571.09 total
Capital at risk
IG Share Dealing logo £0 £250 £21.03
£2,579.34 total
Capital at risk
Freetrade logo £0 £1 £11.51
£2,569.81 total
Capital at risk
Fineco logo £0 No minimum £25.58
£2,583.88 total
Capital at risk
Hargreaves Lansdown Fund and Share Account logo £0 £1 £37.53
£2,595.83 total
Capital at risk
Degiro Share Dealing logo £0 £0.01 £2.56
£2,560.86 total
Capital at risk
interactive investor Trading Account logo £9.99 per month No minimum £46.36
£2,604.67 total
Capital at risk
Stake logo £0 £50 £12.79
£2,571.09 total
Capital at risk
Halifax Share Dealing Account logo £36 per year £20 £41.48
£2,599.78 total
Capital at risk

Full comparison of share dealing platforms

Regeneron Pharmaceuticals share price (NASDAQ:REGN)

Use our graph to track the performance of REGN stocks over time.

Regeneron Pharmaceuticals price performance over time

Historical closes compared with the last close of $623.9

1 week (2022-08-05) 1.68%
1 month (2022-07-12) 2.26%
3 months (2022-05-11) 1.77%
6 months (2022-02-09) 0.67%
1 year (2021-08-12) 2.62%
2 years (2020-08-12) 1.89%
3 years (2019-08-12) 110.87%
5 years (2017-08-11) 33.71%

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

eToro Free Stocks

Invest in Regeneron Pharmaceuticals shares with 0% commission

  • Start investing from as little as $10
  • Pay no stamp duty on UK shares
  • Join 25 million users who trust their investments with eToro
Other fees apply. Capital at risk

All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.

Is Regeneron Pharmaceuticals under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.

P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Regeneron Pharmaceuticals shares trade at around 13x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.2981. Higher PEG ratios such as this can be interpreted as meaning the shares offer worse value given the current rate of growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.


Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $7.4 billion (£6 billion).

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.

Total ESG risk score

Regeneron Pharmaceuticals's total ESG risk: 22.33

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 01/01/2019) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Environmental score

Regeneron Pharmaceuticals's environmental score: 1.51/100

Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Social score

Regeneron Pharmaceuticals's social score: 13.94/100

Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Governance score

Regeneron Pharmaceuticals's governance score: 5.88/100

Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Controversy score

Regeneron Pharmaceuticals's controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Regeneron Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.33
Total ESG percentile 26.82
Environmental score 1.51
Environmental score percentile 2
Social score 13.94
Social score percentile 2
Governance score 5.88
Governance score percentile 2
Level of controversy 2

Regeneron Pharmaceuticals shares at a glance

Information last updated 2022-08-11.
Previous close$641.49
Change %-2.7421%
Information last updated 2022-08-08.
52-week range$538.01 - $747.42
50-day moving average$602.432
200-day moving average$633.1092
Wall St. target price$684.36
PE ratio12.6454
Dividend yield$0 (0%)
Earnings per share (TTM)$49.86

Do Regeneron Pharmaceuticals shares pay dividends?

We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Share price volatility

Over the last 12 months, Regeneron Pharmaceuticals's shares have ranged in value from as little as $538.01 up to $747.42. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.2843. This would suggest that Regeneron Pharmaceuticals's shares are less volatile than average (for this exchange).

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site